Table 1 Demographic and Clinical Characteristics of the Study Sample
Variable | No. (%) |
|---|---|
Sex (No. of patient) | |
Female | 18 (42.9 %) |
Male | 24 (57.1 %) |
Age, years (No. of patients) | |
20–59 | 21 (50.0 %) |
60–69 | 10 (23.8 %) |
70–79 | 9 (21.4 %) |
80+ | 2 (4.8 %) |
Diagnosis (No. of eyes) | |
DME | 16 (24.6 %) |
PDR—vitreous hemorrhage | 10 (15.4 %) |
AMD/Wet type | 15 (23.1 %) |
RVO related ME | 14 (21.5 %) |
Chronic CSC | 8 (12.3 %) |
Idiopathic CNV | 2 (3.1 %) |
Drug (No. of eyes) | |
Bevacizumab (0.05 mL) | 50 (76.9 %) |
Ranibizumab (0.07 mL) | 15 (23.1 %) |
Postoperative vitreous regurgitation (No. of eyes) | |
Yes | 11 (16.9 %) |
No | 54 (83.1 %) |